• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在世界最贫穷国家扩大疫苗接种的成本。

The costs of scaling up vaccination in the world's poorest countries.

作者信息

Bishai David, McQuestion Michael, Chaudhry Rochika, Wigton Alyssa

机构信息

The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

出版信息

Health Aff (Millwood). 2006 Mar-Apr;25(2):348-56. doi: 10.1377/hlthaff.25.2.348.

DOI:10.1377/hlthaff.25.2.348
PMID:16522576
Abstract

We examine the relationship between country-level average costs and coverage levels for diptheria-pertussis-tetanus (DTP) vaccines. Coverage data are from the World Health Organization, and cost data are from financial sustainability plans filed with the Global Alliance for Vaccines and Immunization (GAVI) by forty countries from 2000 to 2003. In this data set, average costs are lower for countries that vaccinate more children. At the highest numbers of covered children, there was no trend toward higher average costs. Vaccine programs in this set of poor countries have not yet scaled up to the point at which diminishing marginal returns are observed.

摘要

我们研究了国家层面白喉-百日咳-破伤风(DTP)疫苗的平均成本与覆盖率之间的关系。覆盖率数据来自世界卫生组织,成本数据来自2000年至2003年四十个国家向全球疫苗免疫联盟(GAVI)提交的财务可持续性计划。在这个数据集中,为更多儿童接种疫苗的国家平均成本较低。在最高的儿童覆盖数量时,没有出现平均成本上升的趋势。这组贫困国家的疫苗计划尚未扩大到出现边际收益递减的程度。

相似文献

1
The costs of scaling up vaccination in the world's poorest countries.在世界最贫穷国家扩大疫苗接种的成本。
Health Aff (Millwood). 2006 Mar-Apr;25(2):348-56. doi: 10.1377/hlthaff.25.2.348.
2
Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.发展中国家免疫规划的资金需求:2004 - 2014年视角
Vaccine. 2005 Aug 31;23(37):4610-8. doi: 10.1016/j.vaccine.2005.04.044.
3
Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?在最贫困国家引入新疫苗:我们从全球疫苗免疫联盟(GAVI)在财务可持续性方面的经验中学到了什么?
Vaccine. 2008 Dec 2;26(51):6706-16. doi: 10.1016/j.vaccine.2008.10.015.
4
Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans.免疫规划财务可持续性策略:对50份国家免疫规划财务可持续性计划中的策略进行的综述
Vaccine. 2008 Dec 2;26(51):6717-26. doi: 10.1016/j.vaccine.2008.10.014.
5
Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia.在埃塞俄比亚将白喉、破伤风、百日咳-乙肝- Hib联合疫苗引入国家免疫规划的增量系统成本。
Vaccine. 2009 Feb 25;27(9):1426-32. doi: 10.1016/j.vaccine.2008.12.037. Epub 2009 Jan 13.
6
Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment.疫苗免疫全球联盟对白喉、破伤风和百日咳疫苗接种覆盖率的影响:一项独立评估
Lancet. 2006 Sep 23;368(9541):1088-95. doi: 10.1016/S0140-6736(06)69337-9.
7
Financial challenges of immunization: a look at GAVI.免疫接种的财政挑战:审视全球疫苗免疫联盟
Bull World Health Organ. 2004 Sep;82(9):697-702.
8
The immunization data quality audit: verifying the quality and consistency of immunization monitoring systems.免疫接种数据质量审计:核实免疫接种监测系统的质量与一致性。
Bull World Health Organ. 2005 Jul;83(7):503-10.
9
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.72个符合全球疫苗免疫联盟(GAVI)资助条件的国家中HPV 16、18疫苗接种的健康和经济成果。
Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15.
10
Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.轮状病毒疫苗接种:发展中国家的成本效益及对儿童死亡率的影响
J Infect Dis. 2009 Nov 1;200 Suppl 1:S28-38. doi: 10.1086/605033.

引用本文的文献

1
Microfluidic-Chip-Based Formulation and In Vivo Evaluations of Squalene Oil Emulsion Adjuvants for Subunit Vaccines.基于微流控芯片的亚单位疫苗角鲨烯油乳佐剂的制剂及体内评价
Vaccines (Basel). 2024 Nov 28;12(12):1343. doi: 10.3390/vaccines12121343.
2
Paradoxes in the coevolution of contagions and institutions.传染病与制度的共同进化悖论。
Proc Biol Sci. 2024 Aug;291(2028):20241117. doi: 10.1098/rspb.2024.1117. Epub 2024 Aug 14.
3
A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice.
当在小鼠中用重组巨细胞病毒(CMV)五聚体抗原进行评估时,含有免疫增强剂α生育酚的自乳化佐剂系统比仅含角鲨烯的乳剂诱导出更高的中和抗体反应。
Pharmaceutics. 2023 Jan 10;15(1):238. doi: 10.3390/pharmaceutics15010238.
4
Systematic review of the incremental costs of interventions that increase immunization coverage.系统评价提高免疫覆盖率干预措施的增量成本。
Vaccine. 2018 Jun 14;36(25):3641-3649. doi: 10.1016/j.vaccine.2018.05.030. Epub 2018 May 10.
5
Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.淋巴丝虫病干预措施的经济评价:系统评价和研究需求。
Parasit Vectors. 2018 Feb 1;11(1):75. doi: 10.1186/s13071-018-2616-z.
6
Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope.大规模药物治疗的经济评估:规模经济和范围经济的重要性。
Clin Infect Dis. 2018 Apr 3;66(8):1298-1303. doi: 10.1093/cid/cix1001.
7
The cost determinants of routine infant immunization services: a meta-regression analysis of six country studies.常规婴儿免疫服务的成本决定因素:六项国家研究的元回归分析
BMC Med. 2017 Oct 6;15(1):178. doi: 10.1186/s12916-017-0942-1.
8
Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa.模拟在撒哈拉以南非洲地区引入RTS,S疟疾疫苗相对于扩大其他疟疾干预措施的成本效益。
BMJ Glob Health. 2017 Jan 24;2(1):e000090. doi: 10.1136/bmjgh-2016-000090. eCollection 2017.
9
Narrative review of models and success factors for scaling up public health interventions.扩大公共卫生干预措施的模式与成功因素的叙述性综述。
Implement Sci. 2015 Aug 12;10:113. doi: 10.1186/s13012-015-0301-6.
10
Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies.覆盖率相关边际成本对最优人乳头瘤病毒疫苗接种策略的影响。
Epidemics. 2015 Jun;11:32-47. doi: 10.1016/j.epidem.2015.01.003. Epub 2015 Feb 7.